Biocon Limited

Biocon Limited Founded:1978

 Biocon Ltd. is India’s premier biopharma enterprise focused on innovation to deliver affordable healthcare solutions to patients, partners and healthcare systems across the globe.
Established in 1978 by Ms Kiran Mazumdar-Shaw, Biocon is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases.
Biocon’s key innovations include world’s first Pichia-based recombinant human Insulin, INSUGEN®, insulin analogue Glargine, BASALOG®, and India’s first indigenously produced monoclonal antibody, BioMAb EGFR® , for head & neck cancer. INSUPen® is a next generation affordable insulin delivery device introduced in India by Biocon.
Continuing on its commitment of affordable innovation, Biocon has delivered its second novel biologic, Itolizumab, a ‘first in class’ biologic drug and the world’s only anti-CD6 monoclonal antibody. Itolizumab will be commercialized in India as ALZUMAb™.
Biocon’s consolidated revenue for FY 13 stands at Rs 25380 million (USD 467 million). Biocon is focused on attaining a size of USD 1 billion by 2018.

Financial / Funding data

The company is listed both in BSE and NSE.
Financials of the year ending on 31st March 2014:
Revenue:2,202.50 Cr.
EBIDTA:409.40 Cr
Net Profit/Loss: 329.85 Cr

Employees5001-10000
DescriptionBiocon Limited is India’s premier biopharma enterprise focused on innovation to deliver affordable healthcare solutions to patients, partners and healthcare systems across the globe.

Milestones

 

More Information

Key People

• Ms. Kiran Mazumdar-Shaw - Chairperson & Managing Director
Dr. Arun Chandavarkar - Chief Executive Officer & Joint Managing Director

Products / ServicesSmall Molecules (APIs) - Biosimilars - Branded Formulations - Novel Molecules - Research Services

Contact Details

Location Bangalore
Phone Number+91 80 2808 2808
Company Office Address

Hosur Road,
Electronics City Bangalore,
Karnataka 560100
India

web address: www.biocon.com